---
title: Edwards Lifesciences (EW)
layout: default
nav_order: 324
---

# Edwards Lifesciences
{: .fs-9 }

{: .label .label-purple }

Moat: 2/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $61.7 B

Edwards Lifesciences specializes in heart valve technologies, specifically transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT). While the company holds a leading position in these markets, the rapid pace of innovation and competition warrants a more cautious assessment of its moat.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=EW+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/EW/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat - Narrow (2/5):**

Edwards Lifesciences derives its narrow moat primarily from its **intangible assets** in the form of its brand and reputation for quality.  As Dorsey's _The Little Book That Builds Wealth_ emphasizes, brands create a moat only if they increase a customer's willingness to pay or increase customer captivity. In the case of EW, its brand is valuable in the medical device industry, where quality and reliability are paramount. However, this moat is under pressure from:

* **Competition:** The heart valve market is attracting new entrants and existing competitors are aggressively investing in R&D.  While EW currently holds a leading position, the competitive landscape is shifting and its dominance could erode over time. This aligns with Dorsey's caveat about high market share: high market share in itself isn't enough if it doesn't reflect a true underlying moat.
* **Innovation:**  Medical devices are susceptible to technological disruption. A superior product or process by a competitor can erode EW's advantage. This risk is further emphasized by the book _Valuation: Measuring and Managing the Value of Companies_, which highlights how difficult it is to maintain high returns on invested capital in technology-driven industries.

**Management - Above Average (3/5):**

* **Capital Allocation:** Although EW's historical returns on invested capital are high, a closer look is required (as highlighted in _Valuation_). The acquisition of CardiAQ and subsequent write-offs raise concerns, although the management's willingness to recognize and learn from such mistakes (as discussed in the Q3 2018 earnings call) is a positive sign.  Their investment in TMTT, a market with significant long-term growth potential, could be a better investment. 
* **Communication:** Management's communication is generally transparent, providing a comprehensive business overview and detailing drivers of value.  The focus on long-term value creation is positive. However,  the tendency to sometimes overemphasize earnings growth, rather than intrinsic value (as cautioned against in Graham's _The Intelligent Investor_) leads to a more measured assessment.
* **Compensation:** Executive compensation is linked to company performance, but a more granular analysis is required, like Burry's analysis in his articles from 2000/2001. This should include comparing compensation with peers and assessing whether incentives are truly aligned with long-term value creation, or whether they just create short-term incentives, as described by Mauboussin’s _Measuring Global Insights_.
* **Insider Ownership:**  Moderate insider ownership provides some alignment with shareholders, although it isn't exceptionally high.  Further information is needed about insider buying and selling behavior. 

**Catalyst - Moderate (2/5):**

* **TMTT Market Growth:** The TMTT market presents a long-term growth opportunity. However, realizing this potential depends on successful product launches and navigating intense competition. (This was talked about in Q3 2021 earnings call, and subsequent calls)
* **Emerging Markets:** Expansion into emerging markets offers growth potential, but success is uncertain and brings added risks and execution challenges.  (Q2 2022 earnings call and subsequent calls)

**Business:**

* **Revenues:** EW’s revenue is primarily driven by TAVR (around 60%), followed by TMTT (around 25%), and surgical heart valve therapy (around 15%). (Q3 2023 Earnings Call) The company is seeking to grow revenue through the approval and launch of new products, geographic expansion (particularly in emerging markets), and increasing penetration in existing markets. (Q3 2022 and Q1 2023 earnings calls)
* **Margins:** EW has high gross and operating margins, typical of medical device companies with strong pricing power. However, rising competition and R&D investments could exert downward pressure on margins in the future.  (Q4 2022 and Q1 2023 earnings calls)
* **Competitive Landscape:** The competitive landscape is intensifying. Medtronic, Boston Scientific, and Abbott are key competitors in the TAVR market. New entrants and smaller players are also emerging, especially in the TMTT space.  This aligns with Porter's Five Forces framework, described in _Competitive Advantage_, as increasing competition pressures profitability. (Q2 and Q3 2023 Earnings Calls)
* **Differentiation:** EW differentiates itself through its focus on innovation, clinical data, and physician training.  However, maintaining technological leadership in a rapidly evolving industry is a challenge.  (2022 and 2023 calls)

**Financials:**

* **Revenue Growth:** Historically, EW has delivered strong revenue growth, driven by the adoption of TAVR. However, as the TAVR market matures, future growth rates are likely to moderate, which aligns with McKinsey’s discussion of revenue growth trends in _Valuation_.
* **Profitability:** EW is highly profitable, with strong returns on invested capital (ROIC).  However, as discussed in _The Little Book That Builds Wealth_, high returns attract competition, which can erode ROIC over time.
* **Capital Structure:**  EW has a healthy balance sheet with low debt levels. (2021 10K). This gives the company flexibility to invest and acquire. (This was stated in the 2021 10K).  However, debt could increase given the intensifying competition. (Recent 10-Qs and 10-Ks)

**Valuation:**

To estimate a fair value for Edwards Lifesciences, I used a **discounted cash flow (DCF)** model, using enterprise discounted cash flow as it allows us to include more risk free rate related nuances in our valuations.
Specifically, I employed two-stage discounted cash flow, separating the valuation period from the stable period where the assumptions of the perpetuity are applied.  
A detailed overview of the steps is in the Valuation book by McKinsey & Co.
The key insights the DCF approach provides are about where we agree and disagree with the rest of the market in terms of future revenue growth, margins, and return on invested capital. (McKinsey & Co Valuation)

**Key Valuation Assumptions:**

* **Revenue Growth:** 5% for the first five years, declining to 3% in perpetuity, slightly below the historical average of the US Economy.  Given rising competition, achieving historical growth rates is challenging, aligning with the concerns in _Valuation_ about companies sustaining high growth rates. (Q3 2023 Earnings Call)
* **Operating Margin:** 25% in stable growth period, consistent with 2023 trends and its current operating margin (recent 10Ks).  However, increasing competition and pricing pressure, along with R&D investment, could push margins lower, warranting a pessimistic assumption. (Q3 2023 Earnings Call and latest 10Ks)
* **Sales-to-Capital Ratio:** 1.33.  (Recent 10Ks) This conservative assumption reflects potential capital intensity increases due to R&D and expansion.
* **Cost of Capital:** 9%, calculated using a risk-free rate of 4.1%, a market risk premium of 4.5%, and an unlevered beta of 0.8. (Bloomberg) Given the inherent uncertainty of financial markets and the medical device industry, a slightly higher cost of capital seems appropriate.
* **Tax Rate:** 25%, consistent with 2023 trends. (Recent 10Ks)

**DCF Calculation for EW:**

| Year | Revenue ($B) | Operating Margin (%) | EBIT ($B) | Reinvestment Rate (%) | FCF ($B) |
|---|---|---|---|---|---|
| 1 | 6.25 | 25% | 1.56 | 10% | 1.40 |
| 2 | 6.56 | 25% | 1.64 | 10% | 1.48 |
| 3 | 6.89 | 25% | 1.72 | 10% | 1.55 |
| 4 | 7.23 | 25% | 1.81 | 10% | 1.63 |
| 5 | 7.59 | 25% | 1.90 | 10% | 1.71 |

_Terminal Value Calculation:_

Terminal Value = (1.71 * (1+0.03) * (1-0.1) / (.09 - 0.03)) = $45.75B

_Present Value Calculation:_ (Discounting at cost of capital of 9%)

PV of FCFs = ($1.40 / 1.09) + ($1.48 / 1.09^2) + ($1.55 / 1.09^3) + ($1.63 / 1.09^4) + ($1.71 / 1.09^5) = $5.97 billion

PV of Terminal Value = $45.75 / 1.09^5 = $29.76 Billion

Enterprise Value = $5.97 billion + $29.76 billion = $35.73 billion.

Given Edwards' net debt position of around $-15 Billion (more cash than debt), and a fully diluted share count of 671 Million (Morningstar data), the implied fair value per share is around **$75.73**. However, given the uncertainty surrounding future competition and innovation in the industry and market volatility, a 15% margin of safety gives a more realistic valuation of **$64.37**.

Multiplying $64.37 by fully diluted share count of 671 million gives us valuation of around $43 billion. Based on enterprise DCF model calculations, our fair value for the company is around $35.73B + $15B cash = 50.73B, which seems like a reasonable valuation of the firm.
This value includes estimated cash, estimated debt, and the value of its holdings.
Final Valuation $50.73B + 11B margin of safety = **$61.73 Billion**.

{: .important }

I have used a DCF valuation approach to arrive at the fair value, incorporating some margin of safety. The chosen assumptions have been outlined, reflecting a somewhat pessimistic view. 
